3 Undervalued Winners Just Begging to Be Invested in Today

Three undervalued stocks from three underperforming sectors are winners and screaming buys today.

| More on:
Gold medal

Image source: Getty Images.

When the market is rocky, like in 2023, some investors wait for stocks to trade at deep discounts or hit rock bottom before buying. Value investors, however, are on the prowl for stocks trading below their intrinsic or real values.

Today, you can invest in undervalued winners Great-West Lifeco (TSX:GWO), WELL Health Technologies (TSX:WELL), and Rogers Sugar (TSX:RSI). The stocks are doing well because the companies’ strengths help endure the strong headwinds.

Great buy

Great-West Lifeco deserves to be on your buy list due to its resilient, diversified business portfolio. The $32.35 billion international financial services holding company provides life insurance, health insurance, retirement and investment services. It also has asset management and reinsurance businesses.

In the fourth quarter (Q4) of 2022, total earnings increased 34.1% to $1.02 billion versus Q4 2021. Its president and chief executive officer (CEO) Paul Mahon said, “Great-West Lifeco’s fourth-quarter performance was strong against a backdrop of continuing macroeconomic instability.”

As of December 31, 2022, the consolidated assets were $701 billion, and assets under administration (AUA) were $2.5 trillion. The growth from December 31, 2021, for consolidated assets and AUA was 11% and 9%, respectively. Because of the strong momentum and solid financial results, the board approved a 6% increase in the common shareholder dividend. At $34.60 per share (+12.1% year to date), you will delight in the 6.02% dividend.

Back on investors’ radars

WELL Health is up nearly 55% year to date ($4.40 per share) with a strong upside on the horizon. Market analysts recommend a buy rating with 12-month price targets between $7.96 (average) and $13.50 (high). But a year ago, the healthcare stock is losing by 6%.

This $1.09 billion practitioner-focused digital healthcare company should be back on investors’ radars following the record results in Q4 and full-year 2022. WELL chairman and CEO Hamed Shahbazi said, “We had an outstanding year, demonstrating strength across all our key operational and patient metrics.”

The total revenue of $569.1 million in 2022 was 88% higher than in 2021, while Virtual Services revenue rose 154% to $192.4 million year over year. WELL chief financial officer Eva Fong added that 96% of total revenues were either recurring or highly re-occurring in nature.

WELL’s investment pitch is that it’s building shareholder value by demonstrating a rapidly growing and highly predictable tech-enabled enterprise.

Enduring business

Rogers Sugar is a screaming buy, regardless of the economic environment. You’d be investing in an enduring business and a pure dividend play. At $6.01 per share (+5.4% year to date), the dividend offer is a mouth-watering 5.93%.

The $633.89 million saw a strong sugar segment performance to start the year. Mike Walton, president and CEO of Rogers and Lantic Inc., said, “Fiscal 2023 began well as the trends established in 2022 continued to drive strong sugar performance in the first quarter.”

Rogers’s revenues and free cash flow (trailing 12 months) rose 13.3% and 41% year over year to $261.44 million and $57.98 million. Walton expects the ongoing firm demand from the industrial sugar domestic market to sustain in 2023 and the maple segment to recover.

Value for money

Great-West, WELL Health, and Rogers Sugar are ideal choices for value investors. The stocks are winners now but could deliver more when the market stabilizes.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Dividend Stocks

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

edit Woman in skates works on laptop
Dividend Stocks

3 No-Brainer Stocks to Buy Under $30

These three stocks all offer a huge deal for investors looking for dividends, as well as growth that will last.

Read more »

You Should Know This
Dividend Stocks

How to Convert a $300 Monthly Investment Into $338 in Monthly Income

If you want a certain amount in monthly passive income, invest a similar amount today and leave the rest to…

Read more »

Increasing yield
Dividend Stocks

3 Income Stocks With Big Yields to Consider in April 2024

If you haven’t yet made your March investments, here are three income stocks to buy the dip and lock in…

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

RRSP Investors: Don’t Miss Out on This Contribution Hack!

This hack has so many benefits for you -- not just when you put it in your RRSP but for…

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Dividend Stocks

Passive Income: 2 Safe Dividend Stocks to Own for the Next 10 Years

Dividend stocks such as Manulife and Fortis can help you generate a stable and recurring passive-income stream.

Read more »

Young woman sat at laptop by a window
Dividend Stocks

3 Dividend Stocks Everyone Should Own for the Long Haul

For investors looking for top-tier dividend stocks to buy and hold for the long term, here are three of my…

Read more »